Relying on Renagel
Executive Summary
In the second of a two-part series focused on Genzyme's European operations, In Vivo Europe Rx looks at how Genzyme is addressing the challenges facing Renagel's uptake in Europe-cost-conscious reimbursement authorities, cheaper competitors and conservative physicians-in order to secure its most important mid-term growth source.You may also be interested in...
Actelion: Pharmacovigilant
Behave, Pharma: Why Culture Is Top Of The List
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.
In US Drug Pricing Debate, ICER’s Voice Gets Louder
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.
Need a specific report? 1000+ reports available
Buy Reports